Risperidone- and quetiapine-induced cholestasis

Annals of Pharmacotherapy

Volumn 41, Issue 9, 2007, Pages 1518-1523

  Wright, Tara M ^a,b   Vandenberg, Amy M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cholestasis; Hepatotoxicity; Quetiapine; Risperidone

Indexed keywords

ALKALINE PHOSPHATASE; ALPRAZOLAM; ATYPICAL ANTIPSYCHOTIC AGENT; BILIRUBIN; ENALAPRIL; INSULIN; ISOPHANE INSULIN; LITHIUM; LIVER ENZYME; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGITATION; ALKALINE PHOSPHATASE BLOOD LEVEL; ANXIETY DISORDER; ARTICLE; CASE REPORT; CHOLESTASIS; DRUG WITHDRAWAL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JAUNDICE; LIVER BIOPSY; LIVER FAILURE; LIVER FUNCTION TEST; MALAISE; MALE; NAUSEA; PRIORITY JOURNAL; PRURITUS; SCHIZOAFFECTIVE PSYCHOSIS; SIDE EFFECT; TACHYCARDIA; UPPER ABDOMINAL PAIN;

ADULT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANTIPSYCHOTIC AGENTS; ASPARTATE AMINOTRANSFERASES; CHOLESTASIS; DIBENZOTHIAZEPINES; HUMANS; MALE; RISPERIDONE; SCHIZOPHRENIA;

EID: 34548164533     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K145     Document Type: Article

References (31)

1. Laboratory tests in liver disease. In: Adreoli TE, Bennett JC, Carpenter CC, Plum F, eds. Cecil essentials of medicine. 4th ed. Philadelphia: WB Saunders Company, 1997:321-3.
2. Pae CU, Lim HK, Kim TS, et al. Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone. Int Clin Psychopharmacol 2005;20:173-6.
3. Hummer M, Kurz M, Kurzthaler I, Oberbauer H, Miller C, Fleischhacker WW. Hepatotoxicity of clozapine. J Clin Psychopharmacol 1997;17:314-7.
4. Gaertner I, Altendorf K, Batra A, Gaertner HJ. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. J Clin Psychopharmacol 2001;21:215-22.
5. Mouradian-Stamatiadis L, Dumortier G, Januel D, Delmas BA, Cabaret W. Liver function tests during treatment with antipsychotic drags: a case series of 23 patients. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1409-11.
6. Dorta G, Siebenmann R, Frohli P, Freytag P, Koelz HR. [Clozapine-induced cholestatic jaundice: a case report] German. Z Gastroenterol 1989;27:388-90.
7. Eggert AE, Crismon ML, Dorson PG, Taylor RL. Clozapine rechallenge after marked liver enzyme elevation. J Clin Psychopharmacol 1994;14:425-6.
8. Hovens JE, Vogtlander LM, Verhoeve HA, Thunnissen PL. [Liver cell necrosis during administration of clozapine] Dutch. Ned Tijdschr Geneeskd 1994;138:363-5.
9. Kellner M, Wiedemann K, Krieg JC, Berg PA. Toxic hepatitis by clozapine treatment. Am J Psychiatry 1993;150:985-6.
10. Macfarlane B, Davies S, Mannan K, Sarsam R, Pariente D, Dooley J. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology 1997;112:1707-9.
11. Markowitz JS, Grinberg R, Jackson C. Marked liver enzyme elevations with clozapine. J Clin Psychopharmacol 1997;17:70-1.
12. Schmidt G, Borsch G, Muller KM, Ricken D. [Clozapine-induced cholestatic liver lesions. A case study] German. Dtsch Med Wochenschr 1987;112:844-6.
13. Cadario B. Olanzapine (Zyprexa): suspected serious reactions. CMAJ 2000;163:85-6,89-90.
14. Gonzalez-Heydrich J, Raches D, Wilens TE, Leichtner A, Mezzacappa E. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. J Am Acad Child Adolesc Psychiatry 2003;42:1227-33.
15. Haberfellner EM, Honsig T. Nonalcoholic steatohepatitis: a possible side effect of atypical antipsychotics. J Clin Psychiatry 2003;64:851.
16. Jadallah KA, Limauro DL, Colatrella AM. Acute hepatocellular-cholestatic liver injury after olanzapine therapy. Ann Intern Med 2003;138:357-8.
17. Kolpe M, Ravasia S. Effect of olanzapine on the liver transaminases. Can J Psychiatry 2003;48:210.
18. El Hajj I, Sharara AI, Rockey DC. Subfulminant liver failure associated with quetiapine. Eur J Gastroenterol Hepatol 2004;16:1415-8.
19. Fuller MA, Simon MR, Freedman L. Risperidone-associated hepatotoxicity. J Clin Psychopharmacol 1996;16:84-5.
20. Krebs S, Dormann H, Muth-Selbach U, Hahn EG, Brune K, Schneider HT. Risperidone-induced cholestatic hepatitis. Eur J Gastroenterol Hepatol 2001;13:67-9.
21. Kumra S, Herion D, Jacobsen LK, Briguglia C, Grothe D. Case study: risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 1997;36:701-5.
22. Landau J, Martin A. Is liver function monitoring warranted during risperidone treatment? J Am Acad Child Adolesc Psychiatry 1998;37:1007-8.
23. Phillips EJ, Liu BA, Knowles SR. Rapid onset of risperidone-induced hepatotoxicity (letter). Ann Pharmacother 1998;32:843. DOI 10.1345/aph1.18022
24. Tello FL, Prats CH, Ros NB, et al. Acute cholestatic hepatitis probably associated with risperidone. Int J Psychiatry Med 2005;35:199-205.
25. Whitworth AB, Liensberger D, Fleischhacker WW. Transient increase of liver enzymes induced by risperidone: two case reports. J Clin Psychopharmacol 1999;19:475-6.
26. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.
27. Mohi-ud-din R, Lewis JH. Drag- and chemical-induced cholestasis. Clin Liver Dis 2004;8:95-132.
28. Selim K, Kaplowitz N. Hepatotoxicity of psychotropic drags. Hepatology 1999;29:1347-51.
29. Desmet VJ. Histopathology of chronic cholestasis and adult ductopenic syndrome. Clin Liver Dis 1998;2:249-64,viii.
30. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
31. Dumotier G, Cabaret W, Stamatiais L, et al. Hepatic tolerance of atypical antipsychotic drugs. Encephale 2002;28:542-51.